10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q1 2012

Filing Information

Form Type	10-Q
Accession Number	`0001144204-12-029702`
Period End Date	20120331
Filing Date	20120515
Fiscal Year	2012
Fiscal Period	Q1
XBRL Instance	bpth-20120331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 61 Income Statement 31 Cash Flow Statement 54

Balance Sheet 61 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$576.82K	USD	Point-in-time
Cash	`Cash`	$238.56K	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash	`Cash`	$765.77K	USD	Point-in-time
Cash	`Cash`	$952.25K	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$21.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$153.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$56.33K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$48.44K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$654.15K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.15M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	58.33M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	58.49M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	58.33M	shares	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.87M	USD	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.89M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	58.49M	shares	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$839.57K	USD	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$791.46K	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$2.05M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$2.08M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$3.23M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$2.71M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$58.45K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$121.54K	USD	Point-in-time
Accounts payable - related party	`AccountsPayableRelatedPartiesCurrent`	$67.97K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$46.08K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$70.91K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$41.00K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$52.70K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$64.54K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$39.54K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$316.13K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$246.59K	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$316.13K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$246.59K	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 58,493,920 and 58,325,169 shares issued and outstanding as of 3/31/12 and 12/31/11, respectively	`CommonStockValue`	$58.33K	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 58,493,920 and 58,325,169 shares issued and outstanding as of 3/31/12 and 12/31/11, respectively	`CommonStockValue`	$58.49K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$12.47M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$12.41M	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$9.55M	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$10.07M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$2.91M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$2.46M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.23M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$2.71M	USD	Point-in-time

Income Statement 31 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	20 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$6.30M	USD	20 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$231.31K	USD	1 Quarter
General & administrative	`GeneralAndAdministrativeExpense`	$350.24K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$592.74K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$10.39M	USD	20 Qtrs
Total operating expense	`OperatingExpenses`	$522.63K	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-592.74K	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-10.39M	USD	20 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-522.63K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$191.00	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$529.00	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$76.84K	USD	20 Qtrs
Other income	`OtherNonoperatingIncome`	$244.48K	USD	20 Qtrs
Other expense	`OtherNonoperatingExpense`	$129.00	USD	1 Quarter
Other expense	`OtherNonoperatingExpense`	$180.00	USD	1 Quarter
Other expense	`OtherNonoperatingExpense`	$3.67K	USD	20 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$400.00	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$317.65K	USD	20 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$11.00	USD	1 Quarter
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-522.23K	USD	1 Quarter
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-592.73K	USD	1 Quarter
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-10.07M	USD	20 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.23	USD	20 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberBasicDilutedSharesOutstanding`	49.40M	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberBasicDilutedSharesOutstanding`	43.97M	shares	20 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberBasicDilutedSharesOutstanding`	58.38M	shares	1 Quarter

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-522.23K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-592.73K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.07M	USD	20 Qtrs
Amortization	`AdjustmentForAmortization`	$48.11K	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$839.57K	USD	20 Qtrs
Amortization	`AdjustmentForAmortization`	$51.76K	USD	1 Quarter
Technology impairment	`AssetImpairmentCharges`	$345.00K	USD	20 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$300.00K	USD	20 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$119.98K	USD	1 Quarter
Stock options and warrants	`ShareBasedCompensation`	$2.97M	USD	20 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$19.36K	USD	1 Quarter
Grants receivable	`IncreaseDecreaseInReceivables`	$-244.48K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$21.00K	USD	20 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$-132.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$-88.40K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-21.99K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$7.89K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$56.33K	USD	20 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$246.59K	USD	20 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-69.54K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-58.85K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-124.97K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-400.19K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-5.45M	USD	20 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$884.71K	USD	20 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$25.00K	USD	1 Quarter
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$32.43K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-884.71K	USD	20 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-25.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-32.43K	USD	1 Quarter
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	$435.00K	USD	20 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$15.00K	USD	20 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$49.76K	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$684.61K	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$6.49M	USD	20 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$6.91M	USD	20 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$684.61K	USD	1 Quarter
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$49.76K	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$527.20K	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$576.82K	USD	20 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$-375.43K	USD	1 Quarter
Cash, beginning of period	`Cash`	$576.82K	USD	Point-in-time
Cash, beginning of period	`Cash`	$238.56K	USD	Point-in-time
Cash, beginning of period	`Cash`	$765.77K	USD	Point-in-time
Cash, beginning of period	`Cash`	$952.25K	USD	Point-in-time
Cash, end of period	`Cash`	$576.82K	USD	Point-in-time
Cash, end of period	`Cash`	$238.56K	USD	Point-in-time
Cash, end of period	`Cash`	$765.77K	USD	Point-in-time
Cash, end of period	`Cash`	$952.25K	USD	Point-in-time
Interest	`InterestPaid`	$445.00	USD	20 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	1 Quarter
Income taxes	`IncomeTaxesPaid`	-	USD	20 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	1 Quarter
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	$420.00K	USD	20 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.